354 related articles for article (PubMed ID: 25183481)
1. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
[TBL] [Abstract][Full Text] [Related]
2. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
3. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
4. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
[TBL] [Abstract][Full Text] [Related]
5. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437
[TBL] [Abstract][Full Text] [Related]
6. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM; Christensen BC
Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
[TBL] [Abstract][Full Text] [Related]
7. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
8. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
11. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Sorich MJ; Wiese MD; Rowland A; Kichenadasse G; McKinnon RA; Karapetis CS
Ann Oncol; 2015 Jan; 26(1):13-21. PubMed ID: 25115304
[TBL] [Abstract][Full Text] [Related]
12. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR
PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426
[TBL] [Abstract][Full Text] [Related]
13. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
15. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
16. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
17. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
Oncologist; 2012; 17(1):14. PubMed ID: 22210091
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
20. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
